Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees
2024 due to his attainment of statutory retirement age, and (ii) Mr. Guo Hongxin has resigned as an independent non-executive Director with effect from 21 June 2024 due to having served as an independent non-executive Director for nine years by 24 August 2024. The Board further announced that, with effect from 21 June 2024, (i) Mr. Pan Yuexin ceased to be a member of
the Strategy Committee and (ii) Mr. Guo Hongxin ceased to chair the Remuneration Committee and ceased to be a member of the Audit Committee and the Risk Management and ESG Committee respectively. With effect from 21 June 20234, (i) Mr. Cheung Yiu Leung Andy will be appointed as a new member of the Audit Committee, (ii) Mr. Dai Zumian will be re-designated from a member of the Remuneration Committee to the chairman of the Remuneration Committee and Dr. Shi Chenyang will be appointed as a new member of the Remuneration Committee, (iii) Mr. Cheung Yiu Leung Andy will be appointed as a new member of the Risk
Management and ESG Committee and (iv) Mr. Dai Zumian and Mr. Pan Jiuan will be appointed as new members of the Strategy Committee.